

## **Specification**

[0047] Specifically, anti-LRP antibodies and the LRP antagonist, recombinant receptor associated protein, rRAP, both abolished the vasoactive effect of tPA and TNK-tPA.

Results described in the present invention suggest that the anti-LRP antibodies and/or rRAP prolong the half-life of tPA in the circulation. These results also suggest that anti-LRP antibodies and/or RAP may be used to prolong the half life of scuPA or scuPA/suPAR complex (described in co-pending applications Serial Nos. 09/325,917, filed June 4, 1999, now allowed; 09/968,752, filed October 2, 2001, issued as U.S. Patent No 6,861,054; 09/302,392, July 10, 2001, issued as U.S. Patent No. 6,270,947; and 09/902,135, filed July 10, 2001, abandoned, ; an incorporated herein, by reference, in their entirety).